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Creatine Supplementation Does Not Alter Proliferation or Doxorubicin Sensitivity
of Mammary Carcinoma Cells
Brandon Jones, James Haughian, David Hydock
University of Northern Colorado
School of Sport and Exercise Science

Abstract
Objectives: Doxorubicin (DOX) is an effective chemotherapy drug used to treat breast cancer,
but is limited by detrimental side effects such as cardiotoxicity and skeletal muscle atrophy.
Supplementation with creatine has been shown to protect cardiac and skeletal muscle cells
from the cytotoxic effects of DOX. However, a concern with dietary creatine supplementation in
cancer patients is the possible protection of cancer cells from therapeutic DOX toxicity. Thus,
we investigated the effects of in vitro creatine supplementation on proliferation and survival of
DOX-treated MAT-BIII, rat mammary carcinoma cells. Methods: MATB-III cells were seeded in
triplicate at 15,000 cells/well in a 96-well microplate for an eight day incubation in one of six
treatments: no treatment, 5 nM DOX, 2mM creatine, 2mM creatine + 5 nM DOX, 20mM
creatine, 20mM creatine + 5 nM DOX. Media and treatments were refreshed every 48 hours. An
MTT assay was run on day 8 to assess remaining cell number in each well. The results represent
an average from three time separated experiments, with differences between treatments
identified using a two-way ANOVA (IBM SPSS 27) and a significance threshold of 0.05. Results:
As expected, the number of MAT-BIII cells was significantly reduced (P < .001) after DOX
treatment, consistent with impaired proliferation or cytotoxicity. Neither low nor high-dose
creatine exposure altered the number of cells, or the suppressive effects of DOX as no
interaction between creatine and DOX was identified (P > 0.05). Conclusion: DOX decreased
proliferation of MAT-BIII mammary carcinoma cells, indicating this cell line is sensitive to the
effects of this chemotherapy drug. There was no indication that creatine influenced
proliferation or DOX sensitivity of the mammary carcinoma cells. The absence of an effect in
this experiment suggests that creatine could be supplemented to alleviate the adverse side
effects of DOX treatment in human breast cancer patients. Future research aims to elucidate
further the possible interactions between DOX and creatine in cancer cell metabolism.
Support/Funding Information: This research was supported by the Graduate Student
Association of the University of Northern Colorado.

Methods
Groups
Control
(No treatment)

5nM DOX
(5nM Doxorubicin)

2mM Cr
(2mM Creatine)

2mM Cr + 5nM DOX
(2mM Creatine + 5nM Doxorubicin)

20mM Cr
(20mM Creatine)

20mM Cr + 5nM DOX
(20mM Creatine + 5nM Doxorubicin)

Table 1: MAT-BIII Incubation Groups

Mammary carcinoma cells (MAT-BIII) were grown in minimum essential media
supplemented with 10% fetal bovine essence (FBE) and 1% penicillin/streptomycin. MAT-BIII
cells were plated in triplicate at 15,000 cells/well in a 96 well microplate for an eight day
incubation in one of six treatments: No Treatment (Control), 5 nM DOX, 2mM creatine, 2mM
creatine + 5 nM DOX, 20mM creatine, 20mM creatine + 5 nM DOX. To ensure adequate
substrate concentrations, the treatment media was refreshed every 48 hours.
On day eight of the incubation, an MTT assay was run to examine cellular proliferation and
analyzed using a spectrophotometer at 595 nm. Cell images were taken on the final incubation
day as a visual verification of the MTT assay. The results are a summary of the three, time
separated incubations. The main effects and interaction between DOX and creatine were
identified using a two-way ANOVA (IBM SPSS 27) with a significance set at α= 0.05.

Results

Introduction
Creatine monohydrate is a popular dietary supplement that has traditionally been
used to enhance athletic performance. Supplementing the diet with creatine
increases lean body mass, reduces muscular fatigue, and improves sprint
performance (1, 2). More recently, creatine has gained attention as a possible clinical
supplement in several disorders including cardiovascular disease, muscular dystrophy,
and cancer (3-5). The role of creatine in cancer is particularly interesting because of
its potential to attenuate skeletal muscle wasting and the cardiotoxic effects of
chemotherapy treatments.
Creatine supplementation research has primarily focused on the bioenergetic
benefit of increased phosphocreatine concentrations promoting enhanced ATP
synthesis; however, creatine can also help regulate glycolysis, decrease cytosolic
acidosis, or scavenge reactive oxygen species (6, 7). These protective properties
support the potential use of creatine as an approach to mitigate the negative side
effects commonly observed in cancer patients undergoing chemotherapy treatments.
Doxorubicin (DOX) is a commonly used chemotherapy agent, but its use is limited by
its toxic effects on cardiac and skeletal muscle. Creatine supplementation has been
shown to attenuate DOX-induced skeletal muscle dysfunction and improve cardiac cell
survival (8, 9); however, the effect of creatine supplementation on cancer cell
proliferation and sensitivity to DOX is still unclear.
Cancer progression is known to alter the phosphocreatine system (10). Therefore,
the interaction between cancer and the phosphocreatine system is a potential
concern for creatine supplementation during chemotherapy treatment. Interestingly,
in-vivo studies have demonstrated an ability of creatine supplementation to decrease
tumor growth (11, 12). Alternative in-vitro research, however, indicates that
overexpression of the ubiquitin mitochondrial creatine kinase enzyme enhances
cellular proliferation and inhibits apoptosis in mouse and human breast cancers (13,
14). The phosphocreatine system has also been shown to significantly impact the
sensitivity of cancer cells to DOX. For example, decreasing the expression of cytosolic
ubiquitin creatine kinase in leukemia and ovarian cancer cell lines displayed an
increased sensitivity to DOX (15, 16). The current project aims to further explore the
effect of creatine supplementation on cell proliferation and DOX sensitivity in
mammary carcinoma cells.

Summary and Conclusion

Results

Figure 1. MTT assay. When compared to
Control, the MTT assay of MAT-BIII cells
treated with 5nM DOX revealed a significant
main effect of DOX, consistent with impaired
proliferation (P < .001). MAT-BIII cells
incubated in low creatine (2mM) and high
creatine (20mM) had no significant main
effect on proliferation (P = 0.771).
The cells treated with 5nM DOX and
creatine exhibited no interaction between
creatine and DOX (P = 0.974).

Figure 1: MAT-BIII Doxorubicin (Dox) and Creatine MTT Assay

Figure 2. Cell images of each treatment
on the final day (day 8) of the incubation.
Provided as a visual verification of the MTT
assay.

Control

2mM Creatine

5nM Dox

2mM Creatine + 5nM Dox

20mM Creatine

The 5nM concentration of DOX was observed to be cytotoxic to MAT-BIII
cells over the eight day incubation used in this study. The cytotoxicity was
demonstrated with an MTT assay (Figure 1) and verified with cell
visualization (Figure 2). This low concentration of DOX (5nM) required an
extended period of time (8 days) to decrease cell number significantly and
was selected to give creatine sufficient time to potentially reduce the
cytotoxic effects of DOX.
Neither the low physiological dose of creatine (2mM) nor the high dose of
creatine (20mM) had a significant main effect on the mammary carcinoma
proliferation. This supports the hypothesis that creatine would not affect
mammary carcinoma proliferation in-vitro.
A secondary outcome was to investigate the effect of creatine on MAT-BIII
cell sensitivity to DOX. Creatine did not have a significant interaction with
DOX cytotoxicity. Neither the 2mM nor the 20mM creatine concentration
had a significant effect on DOX in mammary carcinoma cells.
This research suggests that the use of dietary creatine in breast cancer
patients receiving DOX will not impact the anticancer effects of DOX. Future
research is needed to investigate the effect of creatine supplementation and
DOX sensitivity on a variety of cancer cells.
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Figure 2: MAT-BIII Doxorubicin (Dox) and Creatine Incubation Pictures

